We use cookies to understand how you use our site and to improve the overall user experience. This includes personalizing content and advertising. Read our Privacy Policy
Romidepsin is a selective inhibitor of histone deacetylase, approved in the US in 2009 for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated.
CAT No: 10-101-186
CAS No: 128517-07-7
Synonyms/Alias: Romidepsin; FK 228; 128517-07-7; AKOS024457654; KB-80417; Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S;4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl]; cyclic (3-5) disulfide;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C24H36N4O6S2 |
M.W/Mr. | 540.69584 |
Labeling Target | Histone deacetylase |
Application | Romidepsin is for the treatment of cutaneous T-cell lymphoma (CTCL) or/and peripheral T-cell lymphoma (PTCL) in patients who have received at least one prior systemic therapy. These indications are based on response rate. Clinical benefit such as improvement in overall survival has not been demonstrated. |
Appearance | white to off-white solid powder |
Purity | >98% (or refer to the Certificate of Analysis) |
Activity | Inhibitor |
Biological Activity | Romidepsin (FK 228) is a Histone deacetylase (HDAC) inhibitor with anti-tumor activities. Romidepsin (FK 228) inhibits HDAC1, HDAC2, HDAC4, and HDAC6 with IC50s of 36 nM, 47 nM, 510 nM and 1.4 μM, respectively. Romidepsin (FK 228) is produced by Chromobacterium violaceum, induces cell G2/M phase arrest and apoptosis. |
Areas of Interest | Cutaneous T-cell lymphoma; peripheral T-cell lymphoma |
Functions | Transcription regulatory region sequence-specific dna binding |
Target | HDAC |
Source# | Synthetic |
Long-term Storage Conditions | Soluble in DMSO, not in water |
Shipping Condition | Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs. |
Short-term Storage Conditions | Dry, dark and at 0 - 4 °C |
Solubility | -20 °C |
Organism | Human |
InChI | InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1 |
InChI Key | OHRURASPPZQGQM-GCCNXGTGSA-N |
Isomeric SMILES | C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C |
BoilingPoint | 942.8±65.0 °C at 760 mmHg |
ShelfLife | >2 years if stored properly |
Melting Point | N/A |
3. Emu oil in combination with other active ingredients for treating skin imperfections
4. Emerging applications of nanotechnology for diagnosis and therapy of disease: a review
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com